The Classical Complement Pathway Does NOT Appear Significantly Involved in IgA Nephropathy Pathogenesis
The classical complement pathway is not significantly involved in IgA nephropathy pathogenesis, while the alternative and lectin pathways are the primary drivers of complement-mediated injury. This distinction has critical therapeutic implications as complement-targeted therapies are now entering clinical practice for IgAN.
Evidence for Pathway-Specific Involvement
Alternative and Lectin Pathways: The Main Actors
The evidence consistently demonstrates that the alternative and lectin pathways are the dominant complement activation mechanisms in IgAN 1, 2. Immunofluorescence studies of renal biopsies show deposition of pathway-specific markers:
- Alternative pathway components: Properdin and factor H are present in mesangial immunodeposits 2
- Lectin pathway components: Mannan-binding lectin (MBL), MBL-associated serine proteases (MASP-1 and MASP-2), and C4d are found in glomerular deposits 2
The alternative pathway can initiate activation independently rather than acting solely as an amplifier 3. Recent research confirms that the alternative pathway serves as the dominant pathway, while the lectin pathway also contributes significantly to renal injury 4.
Classical Pathway: Notably Absent
While C3 is routinely present in IgAN biopsies (differentiating true IgAN from subclinical IgA deposition), the classical pathway markers are conspicuously absent or minimal 5. The immunofluorescence pattern in IgAN shows dominant or co-dominant IgA with C3, but C1q is notably absent or present only rarely 6. This contrasts sharply with lupus nephritis, where multiple immunoglobulin classes including IgG, IgA, IgM are present along with C1q, indicating classical pathway activation 6.
Mechanistic Understanding
Why Alternative and Lectin Pathways Are Activated
IgA1 can directly activate both the alternative and lectin pathways in vitro 2. The pathogenic immune complexes in IgAN consist of galactose-deficient IgA1 (Gd-IgA1) bound by anti-glycan antibodies 2, 3. These complexes trigger complement activation through:
- Lectin pathway: Recognition of aberrant glycosylation patterns on Gd-IgA1 by MBL and other pattern recognition molecules 7
- Alternative pathway: Direct activation on IgA1-containing immune complexes, with genetic evidence showing that deletion of complement factor H-related genes 1 and 3 is protective 2
Why Classical Pathway Is Not Involved
The classical pathway typically requires IgG or IgM immune complexes for C1q binding and activation. In IgAN, the dominant immunoglobulin is IgA, which does not efficiently activate the classical pathway 3. The absence of C1q in most IgAN biopsies provides direct pathological evidence that this pathway is not significantly engaged 6.
Clinical and Therapeutic Implications
Biomarker Significance
The presence of C3 without C1q in renal biopsies helps differentiate IgAN from other glomerulonephritides 5. Markers of alternative and lectin pathway activation in renal biopsy specimens are associated with disease activity and worse renal outcomes 5, 8.
Targeted Therapy Development
Understanding which pathways are involved has guided therapeutic development. Current complement inhibitors in clinical trials for IgAN specifically target the alternative and lectin pathways 9:
- Factor B inhibitors (e.g., iptacopan - the first FDA-approved complement inhibitor for IgAN) target the alternative pathway 9
- MASP-2 inhibitors target the lectin pathway 3
- C5 and C5aR inhibitors target the common terminal pathway downstream of both alternative and lectin activation 9, 3
Notably, no therapies targeting the classical pathway (such as C1 inhibitors) are being developed for IgAN, reflecting the lack of evidence for classical pathway involvement 9, 3.
Common Pitfall to Avoid
Do not assume that all complement-mediated glomerular diseases involve the same pathways. The presence of C3 deposition does not indicate classical pathway activation - C3 can be deposited through alternative or lectin pathway activation alone. Always look for C1q on immunofluorescence to assess classical pathway involvement; its absence in the context of IgA and C3 deposition confirms the diagnosis of IgAN rather than lupus nephritis or other classical pathway-mediated diseases 6.